Please login to the form below

Not currently logged in
Email:
Password:

Cipla

This page shows the latest Cipla news and features for those working in and with pharma, biotech and healthcare.

Pharma must do more on antibiotic resistance, Davos meeting hears

Pharma must do more on antibiotic resistance, Davos meeting hears

although Mylan, Cipla and Fresenius Kabi are doing the best when it comes to ‘stewardship’.

Latest news

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    contingent payments for the ADHD company Neurovance; Shanghai Fosun paid $90m for a majority interest in Breas (see above); Ascendis Health paid R375m ($29m) for the Southern Africa operations of Cipla ... 60. Cipla Agrimed. Ascendis Health. Acquisition.

  • Pharma deals in September 2015 Pharma deals in September 2015

    Collaboration - option to license. 555. Hetero Drugs. Cipla. Generic US based companies; InvaGen Pharmaceuticals and Exelar Pharmaceuticals.

  • Pharma deals during November 2012 Pharma deals during November 2012

    The second generics acquisition is the offer of $215m by India's Cipla for a 51 per cent stake in South Africa's third largest drug company Cipla Medpro, again driven ... 230. Cipla Medpro / Cipla. Acquisition. Generics. 215. Ensemble Therapeutics /

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Cipla names Adil Zainulbhai to board Cipla names Adil Zainulbhai to board

    Cipla names Adil Zainulbhai to board. He has experience at consulting firm McKinsey &Company. ... India-based pharma company Cipla has appointed Adil Zainulbhai to its board as an independent director.

  • Cipla appoints Novartis’ Subhanu Saxena as CEO Cipla appoints Novartis’ Subhanu Saxena as CEO

    Cipla appoints Novartis’ Subhanu Saxena as CEO. Was previously head of global product strategy and commercialisation at Swiss pharma firm. ... Subhanu Saxena has left Novartis to join India-based generics company Cipla as its new CEO.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest from PMHub

  • Exploring MINT: Part 3 - Nigeria

    At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

  • Exploring MINT: Part 3 - Nigeria

    At present, antiretroviral treatment is primarily funded by philanthropic organisations, with generic companies such as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics